Emergent Transcatheter Mitral Valve-in-Valve Implantation in a Patient With Cardiogenic Shock Secondary to a Failed Mitral Bioprosthesis
Emergent Transcatheter Mitral Valve-in-Valve Implantation in a Patient With Cardiogenic Shock Secondary to a Failed Mitral Bioprosthesis
复制标题
DOI：
10.1002/ccd.26040
复制
发表时间：
2016-06-01
影响因子：
2.3
通讯作者：
Davies, James
中科院分区：
文献类型：
--
作者：
Alli, Oluseun;Booker, Oscar;Davies, James
经导管瓣膜内植入术（VIV）正在成为治疗高风险或无法进行瓣膜置换术的生物假体失败的一种治疗选择。它可以在任何位置的合适的生物假体瓣膜中进行，通常作为选择性或半选择性手术进行。在这里，我们报告一例急诊经导管VIV植入二尖瓣生物假体失败的危重病人心源性休克。我们的结论是，经导管VIV植入也可能是生物假体失败的危重患者的一种选择。(C) 2015 Wiley期刊公司
Transcatheter valve-in-valve (VIV) implantation is emerging as a therapeutic option for treatment of failed bioprosthesis in patients that are deemed high-risk or inoperable for redo-valve replacement. It can be carried out in suitable bioprosthetic valves in any position and usually performed as an elective or semi-elective procedure. Here, we report a case of emergent transcatheter VIV implantation in a failed mitral bioprosthesis in a critically ill patient with cardiogenic shock. We conclude that transcatheter VIV implantation may also be an option for critically ill patients with failing bioprosthesis. (C) 2015 Wiley Periodicals, Inc.